double-blind study
A double-blind study is a trial deliberately designed so that neither the patient nor the people treating and assessing them know who is getting the real drug and who is getting the comparison, such as a placebo. The blindfold is the point: expectation is a powerful force in medicine, and hiding the assignment stops hope, bias, and the wish for a drug to succeed from quietly shaping the results.
Without blinding, both sides can skew an outcome. A patient who knows they got the active drug may feel better simply from believing in it, and a doctor who knows the assignment may, even unconsciously, treat groups differently, ask leading questions, or judge fuzzy outcomes like 'pain' or 'improvement' more generously. By keeping everyone in the dark, a double-blind design ensures that any measured difference is more likely to come from the drug itself.
In practice, the treatments are made to look, taste, and be given identically, and a separate party holds the code that links each patient to their group. The code is broken only after the data are collected, or sooner for an individual if a medical emergency makes it necessary. This contrasts with a single-blind study, where only the patients are kept unaware.
Blinding is not always possible or perfect. A drug with an obvious side effect, a distinctive taste, or a surgical comparison can give away the assignment, and a clever participant may guess. Honest trials check whether blinding actually held and acknowledge that an unblinded or imperfectly blinded study is more vulnerable to bias.
In a double-blind antidepressant trial, the active pills and placebo are made identical, and neither patients nor psychiatrists know who received which until the study ends and the code is unsealed.
Hiding the assignment from both sides guards against the expectation effect.
When even the statisticians analyzing the data are kept unaware of the group labels, the study is sometimes called triple-blind.